Aware Super Pty Ltd as trustee of Aware Super Has $4.75 Million Position in Neurocrine Biosciences, Inc. $NBIX

Key Points

• Aware Super Pty Ltd significantly increased its stake in Neurocrine Biosciences by 141.2% during the second quarter, holding shares now worth $4.75 million.
• Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences, reducing his ownership by 17.12% and retaining approximately 514,596 shares.
• Analysts have set a Moderate Buy rating on the stock, with price targets ranging from $145.00 to $175.00, reflecting positive sentiment in the market.

Aware Super Pty Ltd as trustee of Aware Super grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 141.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,795 shares of the company's stock after buying an additional 22,125 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super's holdings in Neurocrine Biosciences were worth $4,750,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Farther Finance Advisors LLC raised its holdings in Neurocrine Biosciences by 39.1% during the first quarter. Farther Finance Advisors LLC now owns 686 shares of the company's stock worth $73,000 after acquiring an additional 193 shares in the last quarter. Fifth Third Bancorp grew its stake in Neurocrine Biosciences by 31.7% in the first quarter. Fifth Third Bancorp now owns 1,056 shares of the company's stock valued at $117,000 after purchasing an additional 254 shares in the last quarter. Mission Wealth Management LP increased its position in shares of Neurocrine Biosciences by 22.1% during the 1st quarter. Mission Wealth Management LP now owns 2,210 shares of the company's stock worth $244,000 after purchasing an additional 400 shares during the last quarter. Sowell Financial Services LLC bought a new stake in shares of Neurocrine Biosciences during the 1st quarter worth approximately $529,000. Finally, QRG Capital Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 7.1% in the 1st quarter. QRG Capital Management Inc. now owns 20,062 shares of the company's stock valued at $2,219,000 after buying an additional 1,330 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the sale, the director owned 514,596 shares of the company's stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Wedbush restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. Truist Financial initiated coverage on shares of Neurocrine Biosciences in a research note on Monday, July 21st. They issued a "buy" rating and a $163.00 target price for the company. Finally, Guggenheim boosted their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Sixteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $163.44.

Neurocrine Biosciences Stock Up 0.4%

Shares of NASDAQ:NBIX opened at $137.73 on Thursday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $154.61. The business has a 50 day moving average of $138.11 and a 200-day moving average of $125.55. The stock has a market cap of $13.66 billion, a PE ratio of 40.75, a P/E/G ratio of 0.99 and a beta of 0.21.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.08. The company had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The firm's quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.63 earnings per share. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.